Evidence map›Paper›PMID 39763867›Full record

ArticlebioRxiv : the preprint server for biology2025

The RNA-binding protein HuR impairs adipose tissue anabolism in pancreatic cancer cachexia.

Paige C Arneson-Wissink, Katherine Pelz, Beth Worley, Heike Mendez, Peter Pham, Parham Diba, Peter R Levasseur, Grace McCarthy, Alex Chitsazan, Jonathan R Brody and 1 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Paige C Arneson-WissinkBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR.ORCID 0000-0002-2706-9652
Katherine PelzBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR.
Beth WorleyBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR.
Heike MendezBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR.
Peter PhamBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR.
Parham DibaBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR.
Peter R LevasseurBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR.
Grace McCarthyBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR.
Alex ChitsazanCancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR.
Jonathan R BrodyBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR.
Aaron J GrossbergBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR.ORCID 0000-0003-4690-4948

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9M
PQ6: Therapeutic approaches for autonomic and neuroendocrine dysfunction in cancer cachexiaR01CA264133 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GROSSBERG, AARON · 2021 to 2025
$2.1M
High Performance Computing and Machine Learning Infrastructure for Oregon Life SciencesS10OD034224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE · 2023 to 2023
$2.0M
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancerR01CA212600 · NCI · THOMAS JEFFERSON UNIVERSITY · PI BRODY, JONATHAN · 2017 to 2021
$1.9M
Metabolic vulnerability due to dysregulated lipid metabolism in PDAC cachexiaR37CA280692 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Aaron Grossberg · 2023 to 2026
$1.5M
Hepatic metabolic reprogramming drives pancreatic cancer cachexiaK08CA245188 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GROSSBERG, AARON · 2020 to 2024
$1.2M
Developing a patient derived model platform to treat BRCA1/2-mutant pancreatic cancersR21CA263996 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, SEARS, ROSALIE C · 2022 to 2023
$370k
Elucidating the role of hepatic ketogenesis in pancreatic cancer cachexia and recoveryK99CA286709 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI ARNESON-WISSINK, PAIGE C · 2024 to 2025
$236k
NCI NIH HHS K08 CA245188NCI NIH HHS K99 CA286709NCI NIH HHS P30 CA069533NCI NIH HHS R01 CA212600NCI NIH HHS R01 CA264133NCI NIH HHS R21 CA263996NCI NIH HHS R37 CA280692NCI NIH HHS U01 CA224012NIH HHS S10 OD034224
6 · The paper itself

Abstract

Background: Cachexia is defined by chronic loss of fat and muscle, is a frequent complication of pancreatic ductal adenocarcinoma (PDAC), and negatively impacts patient outcomes. Nutritional supplementation cannot fully reverse tissue wasting, and the mechanisms underlying this phenotype are unclear. This work aims to define the relative contributions of catabolism and anabolism to adipose wasting in PDAC-bearing mice. Human antigen R (HuR) is an RNA-binding protein recently shown to suppress adipogenesis. We hypothesize that fat wasting results from a loss of adipose anabolism driven by increased HuR activity in adipocytes of PDAC-bearing mice. Methods: Adult C57BL/6J mice received orthotopic PDAC cell ( Results: 3T3-L1 adipocytes treated with PDAC cell conditioned media (CM) liberated less triglyceride into the culture media than control-treated adipocytes (-28.1%) and had lower expression of lipolysis and lipogenesis genes than control cells. PDAC gWAT cultured Conclusions: Our work highlights deficient adipose anabolism as a driver of lipid-droplet loss in 3T3-L1 adipocytes treated with PDAC conditioned media and PDAC mice. The small molecule KH-3, which disrupts HuR binding, restored adipose anabolism in PDAC mice. This highlights HuR as a potentially targetable regulatory node for adipose anabolism in cancer cachexia.

Indexed as

adipogenesisadiposecachexiaHuRpancreatic ductal adenocarcinoma

Identifiers

PMID39763867
PMCPMC11703191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.